Form 8-K





Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 22, 2017



Presbia PLC

(Exact name of registrant as specified in its charter)




Ireland   001-36824   98-1162329

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)

120/121 Baggot Street Lower

Dublin 2 Ireland

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: +353 (1) 659 9446

Not Applicable

(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 8.01 Other Events

On February 22, 2017, the Company issued a press release announcing the extension of the subscription period for the currently ongoing rights offering, a copy of which is attached as Exhibit 99.1 hereto. The subscription period will be extended from February 23, 2017 to 5:00 p.m. Eastern Time on March 8, 2017.

Item 9.01 Financial Statements and Exhibits


(d) Exhibits.

99.1 Presbia PLC press release dated February 22, 2017.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: February 22, 2017     By:   /s/ Jarett Fenton
      Jarett Fenton
      Chief Financial Officer







99.1    Presbia PLC press release dated February 22, 2017





DUBLIN, Ireland—(February 22, 2017)—Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration, today announced that it has extended the shareholder rights offering for up to 4,500,000 of its ordinary shares from the previous expiration date of February 23, 2017, until 5:00 p.m., Eastern Time, on Wednesday, March 8, 2017. Shareholders desiring to exercise their rights must submit their subscription documents before the new expiration date of 5:00 p.m. Eastern Time, on Wednesday, March 8, 2017.

The purpose of the extension of the subscription period is to afford Presbia shareholders sufficient time to participate in the rights offering if they wish to do so. The Company believes that some shareholders who hold their shares through brokerage accounts, or other “street name” accounts may have only recently received notification from their broker of the availability of their rights.

A prospectus and related offering materials were mailed to persons who directly hold Presbia common stock “record holders” and are entitled to at least one right. Alternatively, persons who hold their shares through a broker or other firm should have received information concerning the rights offering from their broker and must contact their broker to exercise their basic subscription or oversubscription rights prior to the extended offering expiration date of 5:00 p.m., Eastern Time, on Wednesday, March 8, 2017.

Under the rights offering, Presbia distributed, at no charge, 0.335297256 subscription rights for each ordinary share owned at 5:00 PM Eastern Time on February 6, 2017, the record date for this rights offering. Under the rights offering, Presbia plans to offer up to 4,500,000 ordinary shares. No fractional shares will be issued. The subscription price per whole share is $3.00. Holders who exercise their subscription rights in full will be entitled, if available, to subscribe for additional ordinary shares that are not purchased by other shareholders.

A registration statement relating to the securities has been filed with the Securities and Exchange Commission and was declared effective by the Securities and Exchange Commission on January 26, 2017. The registration statement is available on the SEC’s web site at The rights offering is being made only by means of a written prospectus forming part of the effective registration statement. Copies of the written prospectus for the rights offering may be obtained, when available, by contacting Georgeson LLC, the information agent, at (866) 628-6024.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the shares, nor shall there be any sale of these securities in any state in which such offering, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any state or jurisdiction. The rights offering will be made only by means of a prospectus, copies of which have been mailed to eligible record date stockholders. Investors should consider the Company’s objectives and risks carefully before investing.

Forward-Looking Statements

This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements related to anticipated dates for the rights offering and anticipated uses of proceeds from rights offering. Information provided and statements contained in this press release that are not purely historical are forward-looking statements. Such forward-looking statements only speak as of the date of this press release and Presbia assumes no obligation to update the information included in this press release. Statements made in this press release that are forward-looking in nature may involve risks and uncertainties, including, but not limited to, the factors listed under “Risk Factors” in our annual report on Form 10-K and quarterly reports on Form 10-Q, as well as the Registration Statement on Form S-1, declared effective by the Securities and Exchange Commission on January 26, 2017. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although Presbia believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Unless otherwise required by law, Presbia also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this press release.

About Presbia

Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens™ has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.

Presbia PLC

Jarett Fenton, 949-502-7036

[email protected]